Gov. Mark Gordon sings a ban on the use of abortion pills in Wyoming; a new study shows that Affordable Care Act has reduced racial disparities in health care; California Gov. Gavin Newsom announces a contract to make affordable insulin.
Wyoming Governor Signs Proposed Abortion Pill Ban
Republican Gov. Mark Gordon signed into law a ban on the use of abortion pills in Wyoming, with a separate measure allowing abortion restriction to become law without his signature, according to The Associated Press. This ban would not only prohibit the use of abortion pills in the state starting in July, but also condone legislation banning all abortions. There is no implementation date yet for the all-encompassing abortion ban; abortion remains legal in Wyoming up until viability, or until the fetus would be able to survive outside of the womb.
ACA Reduces Racial Disparities in Health Care
A new report by The Commonwealth Fund shows expanded health insurance under the Affordable Care Act (ACA) reduced racial disparities in health care, according to CBS News. Since its implementation in 2013 allowing Medicaid expansion, the ACA has increased health insurance eligibility among minority individuals and their families. According to the report, "The coverage gap between Black and White adults dropped from 9.9 to 5.3 percentage points, while the gap between Hispanic and White adults dropped from 25.7 to 16.3 points,” according to the study.
California Enters Contract to Make Its Own Affordable Insulin
Gov. Gavin Newsom has announced a contract with nonprofit drugmaker Civica Rx to create California’s own line of affordable insulin for individuals living in the state, according to NPR. The contract will cover 3 forms of insulin: glargine, lispro, and aspart, which are expected to be used interchangeably with other brand name insulins, such as Sanofi’s Lantus, Eli Lilly’s Humalog, and Novo Nordisk’s Novolog, respectively. Once approved by the FDA, California will enter a 10-year contract to create CalRx insulins later this year, with a price tag not to exceed $30 per 10-mL vial.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More